NicOx S.A. (Eurolist: COX) today reported financial results for the twelve months ended December 31, 2006. The Company had cash, cash equivalents and current financial instruments of EUR 81.7 million, compared to EUR 42.6 million on December 31, 2005. This was primarily due to payments received under the major new agreements signed with Pfizer Inc and Merck & Co., Inc. and a EUR 45.5 million private placement financing.
